Table 2 Dosing scheme used for continuous application of selected antibiotics and median serum concentrations of continuously applied piperacillin, ceftazidime, meropenem, and linezolid among patients with and without ECMO support in a pneumological intensive care unit in southwest Germany as compared to pre-defined target serum concentrations, October 2018–December 2019
Antibiotic | Loading dose | Daily dose | Serum target concentration (mg/L) | Patients with ECMO support | Patients without ECMO support | P | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number of patients | Number of TDM measurements | Median serum concentration (mg/L) | Number of patients | Number of TDM measurements | Median serum concentration (mg/L) | |||||||
Normal and moderately impaired renal function | Estimated GFR clearance < 30 ml/min | CRRT | ||||||||||
Ceftazidime | 2 g | 6000 mg | 4000 mg | 6000 mg | ≥ 16 | 7 | 9 | 49.3 (42.0–69.0) | 12 | 15 | 63.2 (38.1–71).0 | 0.69 |
Piperacillin/tazobactam | 4,5 g | 13,500 mg | 9000 mg | 13 500 mg | ≥ 32 | 14 | 31 | 32.3 (26.7–55.9) | 34 | 54 | 52.9 (39.9–87.5) | 0.029 |
Meropenem (standard dose) | 2 g | 3000 mg (standard dose) | 3000 mg | 3000 mg | ≥ 8 | 12 | 33 | 15.0 (11.8–22.2) | 31 | 64 | 17.8 (13.4–32.1) | 0.020 |
Meropenem (high dose) | 2 g | 6000 mg (high dose) | 3000 mg | 6000 mg | ≥ 8 | 6 | 16 | 16.9 (13.7–32.9) | 15 | 33 | 37.8 (22.6–57.8) | 0.372 |
Linezolid | 600 mg | 1800 mg | 1800 mg | 1800 mg | 6.5–12 | 9 | 23 | 8.6 (5.0–10.5) | 10 | 20 | 11.7 (8.3–15.4) | 0.618 |